Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. Sun Pharmaceutical Industries Ltd.
  6. News
  7. Summary
    SUNPHARMA   INE044A01036

SUN PHARMACEUTICAL INDUSTRIES LTD.

(SUNPHARMA)
  Report
Delayed Quote. Delayed NSE India Stock Exchange - 01/14 06:30:27 am
859.75 INR   -0.66%
01/13Indian Benchmarks Extend Gains on Thursday; Tata Steel Jumps 6%
MT
01/04Indian Indices Extend Gains on Tuesday; NTPC Jumps 6%
MT
2021Sun Pharma receives DCGI approval for Molxvir (Molnupiravir) in India
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sun Pharmaceutical Industries Limited Announces the Availability of WINLEVI (Clascoterone) Cream 1% in the United States

10/31/2021 | 10:46pm EST

Sun Pharmaceutical Industries Limited announced the availability of WINLEVI (clascoterone) cream 1% in the United States (U.S). A first-in-class topical androgen receptor inhibitor, WINLEVI was approved by the U.S. Food and Drug Administration (FDA) in August 2020 for the topical treatment of acne vulgaris in patients 12 years of age and older. WINLEVI is the first FDA-approved acne drug with a first-in-class mechanism of action in nearly 40 years. It works by inhibiting the effects of androgen receptors in cells of the sebaceous glands (oil-producing glands in the skin) to help reduce sebum (oil) production and inflammation. It is suitable for use in both males and females.


© S&P Capital IQ 2021
All news about SUN PHARMACEUTICAL INDUSTRIES LTD.
01/13Indian Benchmarks Extend Gains on Thursday; Tata Steel Jumps 6%
MT
01/04Indian Indices Extend Gains on Tuesday; NTPC Jumps 6%
MT
2021Sun Pharma receives DCGI approval for Molxvir (Molnupiravir) in India
AQ
2021Indian Indices Close in Red Midweek; Eicher Motors Climbs 3%
MT
2021Sun Pharmaceutical Industries to Set Up Manufacturing Facility in Andhra Pradesh, India
MT
2021Indian Indices Extend Gains on Tuesday; Asian Paints Climbs 3%
MT
2021Indian shares end higher on upbeat global cues; tech, auto stocks jump
RE
2021Sun Pharmaceutical Industries Gets Emergency Use Authorization to Sell Generic Molnupir..
MT
2021Sun Pharma Receives DCGI Approval for Molxvir® (Molnupiravir) in India
CI
2021Sun Pharma Announces US FDA Approval for Generic Amphotericin B Liposome Injection
AQ
More news
Analyst Recommendations on SUN PHARMACEUTICAL INDUSTRIES LTD.
More recommendations
Financials
Sales 2022 384 B 5 173 M 5 173 M
Net income 2022 70 411 M 950 M 950 M
Net cash 2022 95 711 M 1 291 M 1 291 M
P/E ratio 2022 28,9x
Yield 2022 0,60%
Capitalization 2 063 B 27 836 M 27 819 M
EV / Sales 2022 5,13x
EV / Sales 2023 4,53x
Nbr of Employees 37 000
Free-Float -
Chart SUN PHARMACEUTICAL INDUSTRIES LTD.
Duration : Period :
Sun Pharmaceutical Industries Ltd. Technical Analysis Chart | SUNPHARMA | INE044A01036 | MarketScreener
Technical analysis trends SUN PHARMACEUTICAL INDUSTRIES LTD.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 34
Last Close Price 859,75 INR
Average target price 923,26 INR
Spread / Average Target 7,39%
EPS Revisions
Managers and Directors
Dilip Shantilal Shanghvi Managing Director & Executive Director
C. S. Muralidharan Chief Financial Officer
Israel Makov Non-Executive Chairman
Atanu Roy SVP & Chief Information Officer
Davinder Singh Executive Vice President-Global Operations